News
-
-
PRESS RELEASE
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Jaguar Health announces success of crofelemer powder for oral solution in treating infant patient with congenital sodium diarrhea. Plans for NDA in 2027 for MVID treatment -
-
PRESS RELEASE
Jaguar Health Provides Update Regarding Special Stock Dividend
Jaguar Health, Inc. provides update on special stock dividend payout and ex-dividend date for Series R Convertible Preferred Stock. CEO Lisa Conte comments on company's strategic focus and development program for oral crofelemer -
-
PRESS RELEASE
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Napo Pharmaceuticals presents positive preliminary results for crofelemer powder in Type 1 short bowel syndrome patients at ACG 2026, focusing on reducing ostomy output and improving quality of life -
-
PRESS RELEASE
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
Jaguar Health, Inc. announces Special Stock Dividend for Jaguar Common Stock holders on October 13, 2026, with Record and Payment dates set. Company's CEO Lisa Conte shares perspective on rewarding stockholders and ongoing global development program -
-
PRESS RELEASE
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Jaguar Health announces Napo Pharmaceuticals as sponsor of 2nd Best of Elite Ped-GI Meeting in Abu Dhabi & panel discussion on Intestinal Barrier Beyond TPN. Dr. Miqdady, Dr. Tzivinikos, & Pravin Chaturvedi to participate
